The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates on Giant Cell Arteritis

Updates on Giant Cell Arteritis

March 19, 2018 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Inflammatory infiltrates in the media and adventitia have different composition. T cells are dominant in these lesions, and these T cells may produce IFN-γ, IL-17, IL-21, IL-9, IL-2 and IL-22, a highly diverse effector cell population that suggests multiple antigens are driving disease, “because so many different inflammatory cells are driving the lesion,” said Dr. Weyand. “What the lesion looks like from an immunological perspective is like it is unopposed, or to use a more modern term, like the immune response is ‘unleashed.’ So the question is how can this unleashed immune response get into a site that is normally protected by immune privilege—a site that nature had determined it does not want to have any inflammatory activity for any price?”

You Might Also Like
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • Giant Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment
Explore This Issue
March 2018
Also By This Author
  • New Processes May Stick Around After the Pandemic: Q&A with Wendy Ramey, BSPharm, RPh, CSP

Research findings show three failures in this immune privilege in GCA: Patients have increases in CD4 T cells, a leakiness in the aorta’s access portal that would normally keep out inflammatory cells and defective immune checkpoints.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In their lymphoid tissues, GCA patients have low levels of CD8 T-regulatory cells with a surface marker called NADPH oxidase. Normally, macrophages use this oxidase to form exosomes that infiltrate CD4 cells and stop their function, killing bacteria. Immune dysregulation in GCA causes these patients to have more active CD4 T cells, she said.1

Inflammatory cells enter the aorta through the vasa vasoral networks of the adventitia. Using biopsy data, she and her colleagues found two signals of gene expression in the inflamed arteries of GCA patients: Jagged-1 and NOTCH-1.2 Jagged-1 is the ligand and NOTCH-1 is the receptor, she said. Through high-resolution imaging, they found that Jagged-1 is expressed on the vasa vasorum structures, and the ligand is expressed on the cell surface. With flow cytometry, they also found that the receptor sits on the circulating CD4 T cells of GCA patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We see that patients with GCA have a population of NOTCH-positive cells. If we look in these cells, they have a signal for a protein called HES, which is NOTCH-signaling dependent. Every one of these NOTCH cells is transmitting that signal,” she said. They also found that GCA patients have increased vascular endothelial growth factor (VEGF) that upregulates Jagged-1 on the microvascular cells. Through studies on specially bred mice, the researchers confirmed that both Jagged-1 and NOTCH-1 signaling are VEGF dependent. VEGF increases interferon production in CD3 T cells found in GCA lesions, she said. VEGF may be blocked with axitinib.

Tocilizumab may help GCA patients lower their overall steroid dose & decrease relapse risk.

Checkpoint Breakdown

As in cancer, immune checkpoint function is important in GCA pathogenesis. Tumors evade immune systems by producing negative, inhibitory ligands that stop T cells sent to kill those tumors. In GCA, patients have an immune checkpoint deficiency, said Dr. Weyand. They have low levels of the inhibitory ligand PD-L1 in their inflamed temporal arteries and high levels of the receptor, PD-1.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Meeting Reports, Vasculitis Tagged With: ACR/ARHP Annual Meeting, giant cell arteritis (GCA)Issue: March 2018

You Might Also Like:
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • Giant Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment
  • Varicella Zoster Virus May Cause Giant Cell Arteritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)